Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Jennifer Carroll, Sheryl Coutermarsh-Ott, Shawna L Klahn, Joanne Tuohy, Sabrina L Barry, Irving C Allen, Alayna N Hay, Jeffrey Ruth, Nick Dervisis
PURPOSE: To investigate the safety, feasibility, and outcomes of High-Intensity Focused Ultrasound (HIFU) for the treatment of solid tumors in a spontaneous canine cancer model. METHODS: Dogs diagnosed with subcutaneous solid tumors were recruited, staged and pretreatment biopsies were obtained. A single HIFU treatment was delivered to result in partial tumor ablation using a commercially available HIFU unit. Tumors were resected 3-6 days post HIFU and samples obtained for histopathology and immunohistochemistry...
2022: International Journal of Hyperthermia
#22
REVIEW
Renan Vieira de Brito, Marília Wellichan Mancini, Marcel das Neves Palumbo, Luis Henrique Oliveira de Moraes, Gerson Jhonatan Rodrigues, Onivaldo Cervantes, Joel Avram Sercarz, Marcos Bandiera Paiva
Cisplatin is one of the most widely used anticancer drugs in the treatment of various types of solid human cancers, as well as germ cell tumors, sarcomas, and lymphomas. Strong evidence from research has demonstrated higher efficacy of a combination of cisplatin and derivatives, together with hyperthermia and light, in overcoming drug resistance and improving tumoricidal efficacy. It is well known that the antioncogenic potential of CDDP is markedly enhanced by hyperthermia compared to drug treatment alone...
May 25, 2022: International Journal of Molecular Sciences
#23
Yi-Ting Zhou, Ruo-Yu Wang, Yao Zhang, Dong-Yi Li, Jian Yu
BACKGROUND: Undifferentiated pleomorphic sarcoma (UPS) is a type of soft tissue sarcoma, the histologic origin and differentiation direction of which are still unclear. There are few treatment options for UPS other than surgery. Herein we describe a patient who had multiple recurrences of UPS postoperatively, but R0 resection was achieved by local hyperthermia combined with chemotherapy, thus providing a new treatment approach for similar situations. CASE SUMMARY: A 65-year-old man sought evaluation from a physician for a mass on his right back...
March 26, 2022: World Journal of Clinical Cases
#24
REVIEW
Mark W Dewhirst, James R Oleson, John Kirkpatrick, Timothy W Secomb
Numerous randomized trials have revealed that hyperthermia (HT) + radiotherapy or chemotherapy improves local tumor control, progression free and overall survival vs. radiotherapy or chemotherapy alone. Despite these successes, however, some individuals fail combination therapy; not every patient will obtain maximal benefit from HT. There are many potential reasons for failure. In this paper, we focus on how HT influences tumor hypoxia, since hypoxia negatively influences radiotherapy and chemotherapy response as well as immune surveillance...
March 27, 2022: Cancers
#25
JOURNAL ARTICLE
Christof Boehm, Marianne Goeger-Neff, Hendrik T Mulder, Benjamin Zilles, Lars H Lindner, Gerard C van Rhoon, Dimitrios C Karampinos, Mingming Wu
PURPOSE: MR temperature monitoring of mild radiofrequency hyperthermia (RF-HT) of cancer exploits the linear resonance frequency shift of water with temperature. Motion-induced susceptibility distribution changes cause artifacts that we correct here using the total field inversion (TFI) approach. METHODS: The performance of TFI was compared to two background field removal (BFR) methods: Laplacian boundary value (LBV) and projection onto dipole fields (PDF). Data sets with spatial susceptibility change and <mml:math xmlns:mml="https://www...
July 2022: Magnetic Resonance in Medicine
#26
JOURNAL ARTICLE
Emilie Biele, Sebastian J Schober, Carolin Prexler, Melanie Thiede, Kristina von Heyking, Hendrik Gassmann, Jennifer Eck, Busheng Xue, Stefan Burdach, Uwe Thiel
Ewing's sarcoma (EwS) is a pediatric solid tumor entity with low somatic mutational burden and a low rate of tumor-infiltrating T cells, indicating a low extent of immunogenicity. In EwS, immunogenicity may furthermore be significantly diminished by a predominantly M2 macrophage driven pro-tumorigenic tumor microenvironment. In the past, we demonstrated that CHM1319 -specific TCR-transgenic T cells are able to control EwS growth in a preclinical mouse model as well as in a patient with metastatic disease. However, new adjuvant techniques to induce long lasting and curative CHM1319 -specific TCR-transgenic T cell-mediated anti-tumor responses are needed...
November 8, 2021: Cells
#27
REVIEW
Jan Haussmann, Christiane Matuschek, Edwin Bölke, Balint Tamaskovics, Stefanie Corradini, Rüdiger Wessalowski, Kitti Maas, Livia Schmidt, Klaus Orth, Matthias Peiper, Verena Keitel, Torsten Feldt, Björn-Erik Ole Jensen, Tom Luedde, Johannes Fischer, Wolfram Trudo Knoefel, Hany Ashmawy, Alessia Pedotoa, Kai Kammers, Wilfried Budach
BACKGROUND: The standard treatment of high-risk soft-tissue sarcoma consists of surgical resection followed by risk-adapted radiation therapy. Further treatment options that may improve local and systemic tumor control, including chemotherapy, are not well established. Due to the heterogeneity of the disease, different systemic approaches as well as their application at different time points have been attempted. METHODS: We conducted a systematic literature search for randomized clinical trials in the treatment of localized, resectable high-risk adult soft-tissue sarcoma comparing different treatment modalities according to the PRISMA guidelines...
November 11, 2021: Cancers
#28
JOURNAL ARTICLE
A Willner, K Fechner, A Agaimy, F Haller, M Eckstein, O J Ott, F Putz, U S Gaipl, S Kersting, N Meidenbauer, R Grützmann, R Fietkau, S Semrau
PURPOSE: Retroperitoneal (RPS) sarcomas are associated with poor local and abdominal tumor control. However, the benefit of preoperative radio- or chemotherapy alone for these entities is currently unclear. Moreover, as intermediate- and high-grade sarcomas have a tendency toward early metastasis, exploration of neoadjuvant strategies is of high importance. This analysis reports the results of our 20-year single-institution experience with preoperative neoadjuvant concurrent chemoradiation...
December 2021: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
#29
JOURNAL ARTICLE
Rolf D Issels, Elfriede Noessner, Lars H Lindner, Michael Schmidt, Markus Albertsmeier, Jean-Yves Blay, Emanuel Stutz, Yujun Xu, Veit Buecklein, Annelore Altendorf-Hofmann, Sultan Abdel-Rahman, Ulrich Mansmann, Michael von Bergwelt-Baildon, Thomas Knoesel
BACKGROUND: The EORTC 62961-ESHO 95 randomised trial showed improved long-term survival of patients with high-risk soft-tissue sarcoma by adding regional hyperthermia to neoadjuvant chemotherapy. We hypothesised that immune infiltrate of patients treated with neoadjuvant therapy associate with clinical outcome. METHODS: Tumour infiltrating lymphocytes (TILs) and CD8, FOXP3, PD-1, and PD-L1 were evaluated in sequential biopsies of patients after four cycles of therapy...
October 16, 2021: European Journal of Cancer
#30
JOURNAL ARTICLE
Rebecca Tierce, Tiffany Martin, Kelly L Hughes, Lauren Harrison, Katy L Swancutt, Sangeeta Rao, Del Leary, Susan M LaRue, Mary-Keara Boss
Canine soft tissue sarcoma (STS) has served as a preclinical model for radiation, hyperthermia, experimental therapeutics, and tumor microenvironmental research for decades. Stereotactic body radiotherapy (SBRT) demonstrates promising results for the control of various tumors in human and veterinary medicine; however, there is limited clinical data for the management of STS with SBRT. In this retrospective study, we aimed to define overall efficacy and toxicity of SBRT for the treatment of macroscopic canine STS to establish this preclinical model for comparative oncology research...
December 1, 2021: Radiation Research
#31
JOURNAL ARTICLE
Qian Wang, Xiuying Wu, Xiaogang Zhu, Jian Wang, Feng Xu, Zhenjiang Lin, Chunmei Gong, Min He, Lian Zhang
OBJECTIVE: To investigate the MRI features and clinical outcomes of unexpected uterine sarcomas in patients after high-intensity focused ultrasound (HIFU) ablation for presumed uterine fibroids. MATERIALS AND METHODS: 15,759 consecutive patients who came for HIFU treatment, from November 2008 to September 2019, for presumed uterine fibroids were retrospectively reviewed. All the patients had completed a pre-HIFU MRI. All MRI images were independently analyzed and interpreted by two radiologists in every center...
September 2021: International Journal of Hyperthermia
#32
JOURNAL ARTICLE
Laura V Klotz, Christiane Gruenewald, Elena L Bulut, Florian Eichhorn, Michael Thomas, Rajiv Shah, Mark Kriegsmann, Werner Schmidt, Othmar Kofler, Hauke Winter, Martin E Eichhorn
BACKGROUND: Lung-sparing cytoreductive surgery by extended pleurectomy and decortication (EPD) in combination with hyperthermic intrathoracic chemoperfusion (HITOC) forms a promising treatment strategy for malignant pleural mesothelioma and recurrent pleural thymic malignancies. OBJECTIVES: The objective of this study was to scrutinize the surgical procedure and perioperative patient management with emphasis on perioperative morbidity and local tumor control. METHODS: In 2014, a standardized EPD and HITOC procedure was implemented at the Thoraxklinik Heidelberg...
August 12, 2021: Respiration; International Review of Thoracic Diseases
#33
REVIEW
Alessandro Gronchi
Surgery is the primary treatment for localized, clinically resectable soft tissue sarcoma (STS). Chemotherapy and radiotherapy, administered in the pre- or post-operative settings, have important ancillary roles in the multimodal management of primary STS. Some sarcoma centers also employ locoregional therapies such as isolated limb perfusion and deep wave hyperthermia in multimodal therapy. In advanced or metastatic STS, surgery is recommended when complete resection is feasible. Nevertheless, in certain situations there is thin line between a surgical or non-surgical approach, generally related to STS histological type/subtype, disease stage and technical considerations...
July 2021: Future Oncology
#34
JOURNAL ARTICLE
Mateusz Jacek Spałek, Aneta Maria Borkowska, Maria Telejko, Michał Wągrodzki, Daria Niebyłowska, Aldona Uzar, Magdalena Białobrzeska, Piotr Rutkowski
INTRODUCTION: Management of marginally resectable or unresectable soft tissue sarcomas (STS) in patients who are not candidates for neoadjuvant chemotherapy due to chemoresistant pathology or contraindications remains a challenge. Therefore, in these indications, we aimed to investigate a feasibility of 10x 3.25 Gy radiotherapy combined with regional hyperthermia (HT) that could be followed by surgery or 4x 4 Gy radiotherapy with HT. MATERIALS AND METHODS: We recruited patients with locally advanced marginally resectable or unresectable STS who (1) presented chemoresistant STS subtype, or (2) progressed after neoadjuvant chemotherapy, or (3) were unfit for chemotherapy...
March 16, 2021: Cancers
#35
JOURNAL ARTICLE
Lars H Lindner, Jean-Yves Blay, Alexander M M Eggermont, Rolf D Issels
A group of patients with adult-type soft tissue sarcoma is at high risk of local recurrence and distant metastases. Age, tumour site, histological subtype, tumour size and grade have been identified as the most important independent adverse prognostic factors. Macroscopically complete tumour resection is considered as the mainstay of treatment with the addition of preoperative or postoperative radiotherapy for extremity or trunk localisation. Retroperitoneal localisation requires compartmental resection and is associated with a worse prognosis...
April 2021: European Journal of Cancer
#36
JOURNAL ARTICLE
Giammaria Fiorentini, Donatella Sarti, Cosmo Damiano Gadaleta, Marco Ballerini, Caterina Fiorentini, Tommaso Garfagno, Girolamo Ranieri, Stefano Guadagni
The role of hyperthermia (HT) in cancer therapy and palliative care has been discussed for years in the literature. There are plenty of articles that show good feasibility of HT and its efficacy in terms of tumor response and survival improvements. Nevertheless, HT has never gained enough interest among oncologists to become a standard therapy in clinical practice. The main advantage of HT is the enhancement of chemotherapy (CHT), radiotherapy (RT), chemoradiotherapy (CRT), and immunotherapy benefits. This effect has been confirmed in several types of tumors: esophageal, gastrointestinal, pancreas, breast, cervix, head and neck, and bladder cancers, and soft tissue sarcoma...
January 2020: Integrative Cancer Therapies
#37
REVIEW
Thomas Gp Grünewald, Marta Alonso, Sofia Avnet, Ana Banito, Stefan Burdach, Florencia Cidre-Aranaz, Gemma Di Pompo, Martin Distel, Heathcliff Dorado-Garcia, Javier Garcia-Castro, Laura González-González, Agamemnon E Grigoriadis, Merve Kasan, Christian Koelsche, Manuela Krumbholz, Fernando Lecanda, Silvia Lemma, Dario L Longo, Claudia Madrigal-Esquivel, Álvaro Morales-Molina, Julian Musa, Shunya Ohmura, Benjamin Ory, Miguel Pereira-Silva, Francesca Perut, Rene Rodriguez, Carolin Seeling, Nada Al Shaaili, Shabnam Shaabani, Kristina Shiavone, Snehadri Sinha, Eleni M Tomazou, Marcel Trautmann, Maria Vela, Yvonne Mh Versleijen-Jonkers, Julia Visgauss, Marta Zalacain, Sebastian J Schober, Andrej Lissat, William R English, Nicola Baldini, Dominique Heymann
Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult-to-treat categories...
November 6, 2020: EMBO Molecular Medicine
#38
REVIEW
Mateusz Jacek Spałek, Katarzyna Kozak, Anna Małgorzata Czarnecka, Ewa Bartnik, Aneta Borkowska, Piotr Rutkowski
Due to the heterogeneity of soft tissue sarcomas (STS), the choice of the proper perioperative treatment regimen is challenging. Neoadjuvant therapy has attracted increasing attention due to several advantages, particularly in patients with locally advanced disease. The number of available neoadjuvant modalities is growing continuously. We may consider radiotherapy, chemotherapy, targeted therapy, radiosensitizers, hyperthermia, and their combinations. This review discusses possible neoadjuvant treatment options in STS with an emphasis on available evidence, indications for each treatment type, and related risks...
July 26, 2020: Cancers
#39
JOURNAL ARTICLE
Chiao-Yun Lin, Angel Chao, Ren-Chin Wu, Li-Yu Lee, Shir-Hwa Ueng, Chia-Lung Tsai, Yun-Shien Lee, Meng-Ting Peng, Lan-Yan Yang, Huei-Jean Huang, Hsin-Shih Wang, Chyong-Huey Lai
Pazopanib-a multitargeted tyrosine kinase inhibitor with prominent antiangiogenic effects-has shown promise in the treatment of soft-tissue sarcomas. Hyperthermia has been also applied as an adjunctive treatment to chemotherapy for these malignancies. Here, we show that pazopanib and hyperthermia act synergistically in inhibiting uterine leiomyosarcoma (LMS) cell growth. Compared with either treatment alone, the combination of pazopanib and hyperthermia exerted the highest antitumor activity in a xenograft model...
July 7, 2020: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
#40
REVIEW
K S Martin-Tellez, W J van Houdt, F van Coevorden, C Colombo, M Fiore
Soft tissue sarcomas constitute 1% of adult malignant tumors. They are a heterogeneous group of more than 50 different histologic types. Isolated limb perfusion is an established treatment strategy for locally advanced sarcomas. Since its adoption for sarcomas in 1992, after the addition of TNFα, few modifications have been done and although indications for the procedure are essentially the same across centers, technical details vary widely. The procedures mainly involves a 60 min perfusion with melphalan and TNFα under mild hyperthermia, achieving a limb preservation rate of 72-96%; with an overall response rates from 72 to 82...
August 2020: Cancer Treatment Reviews
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
